Major update in tx for GCA beyond Toci SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission with SHORTER (26wk) steroid use compared to placebo (52wk) No significant adverse safety signal w JAKi including MACE/malignancy @RheumNow #ACR24 Abstract 0770 https://t.co/45D0Txed2N

• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1
• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1

Results from SELECT-GCA ➡️UPA 15mg + 26W GC taper demonstrates superior efficacy & reduced GC use vs PBO + 52W GC taper ➡️No new safety signals Is UPA the new kid on the block in #GCA? Ab0770 #ACRBest #ACR24 @RheumNow https://t.co/pHzozYiid5

• https://x.com/DrMiniDey/status/1857796013395697830/photo/1

The TAPIR Trial on GPA shows higher (15.5%) relapse in the 0 mg prednisone arm vs. 4.2% in the 5 mg arm (OR 4.22), but does not impact PROs. Key finding: benefit of 5 mg/day seen only in non-rituximab regimens (20% vs. 2.6%, OR 9.50). Abstr#0774 Plenary 1 @RheumNow #ACR24… https://t.co/5DjW5Zwh0J https://t.co/UnsVPzJfs6

• https://x.com/i/web/status/1857791986553540805
• https://x.com/synovialjoints/status/1857791986553540805/photo/1

SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0

• https://x.com/ericdeinmd/status/1857794819352825977/photo/1
• https://x.com/ericdeinmd/status/1857794819352825977/photo/1
• https://x.com/ericdeinmd/status/1857794819352825977/photo/1

Upadacitinib in GCA. Merkel et al. SELECT-GCA study. Sustained remission week 52 Upa (+26 week steroid) 46% vs PBO (+52 week steroid) 29%. Reduced flare rates with UPA (see picture). Similar to GiACTA results. @RheumNow #ACR24 Abstr#0770 https://t.co/fr75XK21L1 https://t.co/Hhax7po7vV

• Efficacy and Safety of Upadacitinib in Patients with Giant Cell Arteritis (SELE…
• https://x.com/RichardPAConway/status/1857795258379350260/photo/1

EGPA: To RTX or not to RTX? French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy Huge anticipation for these results, hopefully next year! #ACR24 @RheumNow https://t.co/POelLpirrI

• https://x.com/Dr_Brian_MD/status/1857484737084047833/photo/1

Year in review: The MANDARA trial showed benralizumab was non-inferior to mepolizumab for #EGPA @RheumNow #ACR24 @rheumarhyme @doktora_ging https://t.co/k5azGQOECB

• https://x.com/RHEUMarampa/status/1857773694761762864/photo/1
• https://x.com/RHEUMarampa/status/1857773694761762864/photo/1

Looking forward to this Plenary - upadacitinib vs plbo in GCA Similar to GiACTA, 26wk taper w/UPA better than 52wk taper w/PLBO. Too small for safety, but no new rsks Strong argument for DMARDs upfront in GCA... but doesn't help with which 😉 #ACR24 @RheumNow Abstr#0770 https://t.co/MZY4QUazhI

• https://x.com/EBRheum/status/1857773615619453431/photo/1
• https://x.com/EBRheum/status/1857773615619453431/photo/1

MANDARA Mepolizumab v benralizumab for EGPA BEN is non-inferior Secondary outcomes- less eosinophils and more pts completely off GCs Now approved for EGPA Year in Review #ACR24 Pillinger @RheumNow https://t.co/ThLziABvzu

• https://x.com/ericdeinmd/status/1857773289474507223/photo/1

Abatacept for GPA? Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA Continued need for tx options in non-severe relapsing dz @RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7

• https://x.com/Dr_Brian_MD/status/1857502436371607960/photo/1